Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
复制标题
DOI：
10.1016/j.ccell.2021.12.002
复制
发表时间：
2022-01-10
期刊：
影响因子：
50.3
通讯作者：
CANVAX team
中科院分区：
文献类型：
--
作者：
Naranbhai V;St Denis KJ;Lam EC;Ofoman O;Garcia-Beltran WF;Mairena CB;Bhan AK;Gainor JF;Balazs AB;Iafrate AJ;CANVAX team
癌症患者对SARS-CoV-2疫苗的免疫反应更有可能受损。我们研究了178例不同肿瘤类型的患者初次接种后对SARS-CoV-2变体的反应广度，以及在一个亚组中加强剂量后的反应广度。无论疫苗类型如何，与野生型相比，α、β、γ和δ型SARS-CoV-2变体的中和作用受损。无论病毒变异如何，mRNA1273的免疫原性最强，其次是BNT162b2，然后是Ad26.COV2.S。更多变异的中和（宽度）与更大程度的野生型中和相关，并且随着接种疫苗后的时间而增加；年龄越大，脑宽度越窄。抗刺突蛋白抗体的浓度是宽度的一个很好的替代指标（在1000 U/mL时阳性预测值为90%）。加强SARS-CoV-2疫苗可增强广度。这些数据表明，实现高抗体滴度是实现广泛中和所需要的；当前疫苗的单次加强剂量增加了对变异的反应广度。Naranbhai等人研究了目前基于野生型的SARS-CoV-2疫苗在癌症患者中和病毒变体方面的表现。研究结果支持对高危患者首选免疫原性最强的野生型疫苗（即mRNA1273或BNT162b2），以产生抗变异的广度。
Patients with cancer are more likely to have impaired immune responses to SARS-CoV-2 vaccines. We study the breadth of responses against SARS-CoV-2 variants after primary vaccination in 178 patients with a variety of tumor types and after booster doses in a subset. Neutralization of alpha, beta, gamma, and delta SARS-CoV-2 variants is impaired relative to wildtype, regardless of vaccine type. Regardless of viral variant, mRNA1273 is the most immunogenic, followed by BNT162b2, and then Ad26.COV2.S. Neutralization of more variants (breadth) is associated with a greater magnitude of wildtype neutralization, and increases with time since vaccination; advancing age associates with a lower breadth. The concentrations of anti-spike protein antibody are a good surrogate for breadth (positive predictive value of =90% at >1,000 U/mL). Booster SARS-CoV-2 vaccines confer enhanced breadth. These data suggest that achieving a high antibody titer is desirable to achieve broad neutralization; a single booster dose with the current vaccines increases the breadth of responses against variants. Naranbhai et al. examine how well current wildtype-based SARS-CoV-2 vaccines perform in patients with cancer in neutralizing viral variants. The findings support preferring the most immunogenic wildtype vaccines (i.e., mRNA1273 or BNT162b2) for patients at high risk to generate breadth against variants.
登录
查看更多内容
DOI：
10.1093/infdis/jiab593
发表时间：
2022-04-01
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Naranbhai V;Garcia-Beltran WF;Chang CC;Berrios Mairena C;Thierauf JC;Kirkpatrick G;Onozato ML;Cheng J;St Denis KJ;Lam EC;Kaseke C;Tano-Menka R;Yang D;Pavlovic M;Yang W;Kui A;Miller TE;Astudillo MG;Cahill JE;Dighe AS;Gregory DJ;Poznansky MC;Gaiha GD;Balazs AB;Iafrate AJ
通讯作者：
Iafrate AJ
DOI：
10.1016/s2352-3026(21)00110-1
发表时间：
2021-06
期刊：
The Lancet. Haematology
影响因子：
--
作者：
Bird S;Panopoulou A;Shea RL;Tsui M;Saso R;Sud A;West S;Smith K;Barwood J;Kaczmarek E;Panlaqui C;Kaiser M;Stern S;Pawlyn C;Boyd K
通讯作者：
Boyd K
影响因子：
64.5
作者：
Garcia-Beltran, Wilfredo F.;Lam, Evan C.;Balazs, Alejandro B.
通讯作者：
Balazs, Alejandro B.
影响因子：
50.3
作者：
Thakkar A;Gonzalez-Lugo JD;Goradia N;Gali R;Shapiro LC;Pradhan K;Rahman S;Kim SY;Ko B;Sica RA;Kornblum N;Bachier-Rodriguez L;McCort M;Goel S;Perez-Soler R;Packer S;Sparano J;Gartrell B;Makower D;Goldstein YD;Wolgast L;Verma A;Halmos B
通讯作者：
Halmos B
影响因子：
64.8
作者：
Cho A;Muecksch F;Schaefer-Babajew D;Wang Z;Finkin S;Gaebler C;Ramos V;Cipolla M;Mendoza P;Agudelo M;Bednarski E;DaSilva J;Shimeliovich I;Dizon J;Daga M;Millard KG;Turroja M;Schmidt F;Zhang F;Tanfous TB;Jankovic M;Oliveria TY;Gazumyan A;Caskey M;Bieniasz PD;Hatziioannou T;Nussenzweig MC
通讯作者：
Nussenzweig MC